{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:09:22Z","timestamp":1792951762998,"version":"4.5.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:00:00Z","timestamp":1718409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Neurofibromatosis type 2 (\n                    <jats:italic>NF2<\/jats:italic>\n                    ) is a tumor suppressor gene implicated in various tumors, including mesothelioma, schwannomas, and meningioma. As a member of the ezrin, radixin, and moesin (ERM) family of proteins, merlin, which is encoded by\n                    <jats:italic>NF2<\/jats:italic>\n                    , regulates diverse cellular events and signalling pathways, such as the Hippo, mTOR, RAS, and cGAS-STING pathways. However, the biological role of\n                    <jats:italic>NF2<\/jats:italic>\n                    in tumorigenesis has not been fully elucidated. Furthermore, cross-cancer mutations may exert distinct biological effects on tumorigenesis and treatment response. In addition to the functional inactivation of\n                    <jats:italic>NF2<\/jats:italic>\n                    , the codeficiency of other genes, such as cyclin-dependent kinase inhibitor 2A\/B (\n                    <jats:italic>CDKN2A\/B<\/jats:italic>\n                    ), BRCA1-associated protein-1 (\n                    <jats:italic>BAP1<\/jats:italic>\n                    ), and large tumor suppressor 2 (\n                    <jats:italic>LATS2<\/jats:italic>\n                    ), results in unique tumor characteristics that should be considered in clinical treatment decisions. Notably, several recent studies have explored the metabolic and immunological features associated with\n                    <jats:italic>NF2<\/jats:italic>\n                    , offering potential insights into tumor biology and the development of innovative therapeutic strategies. In this review, we consolidate the current knowledge on\n                    <jats:italic>NF2<\/jats:italic>\n                    and examine the potential connection between cancer metabolism and tumor immunity in merlin-deficient malignancies. This review may provide a deeper understanding of the biological roles of\n                    <jats:italic>NF2<\/jats:italic>\n                    and guide possible therapeutic avenues.\n                  <\/jats:p>","DOI":"10.1038\/s41698-024-00627-5","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T15:01:39Z","timestamp":1718463699000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-1761","authenticated-orcid":false,"given":"Duo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-0877","authenticated-orcid":false,"given":"Yongqian","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,15]]},"reference":[{"key":"627_CR1","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli, A. M. & Fern\u00e1ndez-Valle, C. Role of Merlin\/NF2 inactivation in tumor biology. Oncogene 35, 537\u2013548 (2016).","journal-title":"Oncogene"},{"key":"627_CR2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto, M., Cole, B. K., Lallemand, D., Liu, C.-H. & McClatchey, A. I. Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin. J. Cell Biol. 177, 893\u2013903 (2007).","journal-title":"J. Cell Biol."},{"key":"627_CR3","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.189601","volume":"15","author":"H Morrison","year":"2001","unstructured":"Morrison, H. et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15, 968\u2013980 (2001).","journal-title":"Genes Dev."},{"key":"627_CR4","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/sj.onc.1209849","volume":"26","author":"Y Bai","year":"2007","unstructured":"Bai, Y. et al. Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin. Oncogene 26, 836\u2013850 (2007).","journal-title":"Oncogene"},{"key":"627_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ccr.2014.05.001","volume":"26","author":"W Li","year":"2014","unstructured":"Li, W. et al. Merlin\/NF2 loss-driven Tumorigenesis linked to CRL4DCAF1-mediated inhibition of the Hippo Pathway Kinases Lats1 and 2 in the nucleus. Cancer Cell 26, 48\u201360 (2014).","journal-title":"Cancer Cell"},{"key":"627_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.cell.2010.01.029","volume":"140","author":"W Li","year":"2010","unstructured":"Li, W. et al. Merlin\/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 140, 477\u2013490 (2010).","journal-title":"Cell"},{"key":"627_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.devcel.2010.10.008","volume":"19","author":"AB Gladden","year":"2010","unstructured":"Gladden, A. B., Hebert, A. M., Schneeberger, E. E. & McClatchey, A. I. The NF2 tumor suppressor, merlin, regulates epidermal development through the establishment of a junctional polarity complex. Dev. Cell 19, 727\u2013739 (2010).","journal-title":"Dev. Cell"},{"key":"627_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1006\/geno.2001.6672","volume":"79","author":"LS Chang","year":"2002","unstructured":"Chang, L. S., Akhmametyeva, E. M., Wu, Y., Zhu, L. & Welling, D. B. Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts. Genomics 79, 63\u201376 (2002).","journal-title":"Genomics"},{"key":"627_CR9","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno, R. et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48, 407\u2013416 (2016).","journal-title":"Nat. Genet."},{"key":"627_CR10","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/acn3.51386","volume":"8","author":"P Kukutla","year":"2021","unstructured":"Kukutla, P. et al. Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas. Ann. Clin. Transl. Neurol. 8, 1508\u20131514 (2021).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"627_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2008.08.014","volume":"64","author":"C Thurneysen","year":"2009","unstructured":"Thurneysen, C. et al. Functional inactivation of NF2\/merlin in human mesothelioma. Lung Cancer 64, 140\u2013147 (2009).","journal-title":"Lung Cancer"},{"key":"627_CR12","doi-asserted-by":"crossref","unstructured":"Lee, S. et al. The Role of Merlin\/NF2 Loss in Meningioma Biology. Cancers (Basel) 11, (2019).","DOI":"10.3390\/cancers11111633"},{"key":"627_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/humu.20393","volume":"28","author":"I Ahronowitz","year":"2007","unstructured":"Ahronowitz, I. et al. Mutational spectrum of the NF2 gene: a meta-analysis of 12 years of research and diagnostic laboratory findings. Hum. Mutat. 28, 1\u201312 (2007).","journal-title":"Hum. Mutat."},{"key":"627_CR14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M","volume":"24","author":"JQ Cheng","year":"1999","unstructured":"Cheng, J. Q. et al. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 24, 238\u2013242 (1999).","journal-title":"Genes Chromosomes Cancer"},{"key":"627_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5858\/arpa.2010-0550-RS","volume":"136","author":"SS Chekol","year":"2012","unstructured":"Chekol, S. S. & Sun, C. C. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch. Pathol. Lab Med. 136, 113\u2013117 (2012).","journal-title":"Arch. Pathol. Lab Med."},{"key":"627_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10937404.2011.556051","volume":"14","author":"SXL Huang","year":"2011","unstructured":"Huang, S. X. L., Jaurand, M.-C., Kamp, D. W., Whysner, J. & Hei, T. K. Role of mutagenicity in Asbestos fiber-induced carcinogenicity and other diseases. J. Toxicol. Environ. Health B 14, 179\u2013245 (2011).","journal-title":"J. Toxicol. Environ. Health B"},{"key":"627_CR17","doi-asserted-by":"publisher","first-page":"1161995","DOI":"10.3389\/ftox.2023.1161995","volume":"5","author":"Y Sekido","year":"2023","unstructured":"Sekido, Y. & Sato, T. NF2 alteration in mesothelioma. Front Toxicol. 5, 1161995 (2023).","journal-title":"Front Toxicol."},{"key":"627_CR18","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/ijms19040988","volume":"19","author":"T Sato","year":"2018","unstructured":"Sato, T. & Sekido, Y. NF2\/Merlin inactivation and potential therapeutic targets in Mesothelioma. Int J. Mol. Sci. 19, 988 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"627_CR19","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","volume":"92","author":"AB Bianchi","year":"1995","unstructured":"Bianchi, A. B. et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA 92, 10854\u201310858 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR20","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1038\/sj.onc.1206593","volume":"22","author":"J Fleury-Feith","year":"2003","unstructured":"Fleury-Feith, J. et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 22, 3799\u20133805 (2003).","journal-title":"Oncogene"},{"key":"627_CR21","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ccr.2008.01.030","volume":"13","author":"J Jongsma","year":"2008","unstructured":"Jongsma, J. et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 13, 261\u2013271 (2008).","journal-title":"Cancer Cell"},{"key":"627_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21798-w","volume":"12","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 12, 1751 (2021).","journal-title":"Nat. Commun."},{"key":"627_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00931-w","volume":"13","author":"C Meiller","year":"2021","unstructured":"Meiller, C. et al. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Med. 13, 113 (2021).","journal-title":"Genome Med."},{"key":"627_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes, S. M., Alrifai, D. & Fennell, D. A. Perspectives on the treatment of malignant pleural Mesothelioma. N. Engl. J. Med. 385, 1207\u20131218 (2021).","journal-title":"N. Engl. J. Med."},{"key":"627_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum, Y. et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 10, 1333 (2019).","journal-title":"Nat. Commun."},{"key":"627_CR26","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak, J. et al. Integrative molecular characterization of malignant pleural Mesothelioma. Cancer Discov. 8, 1548\u20131565 (2018).","journal-title":"Cancer Discov."},{"key":"627_CR27","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"Quetel, L. et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol. Oncol. 14, 1207\u20131223 (2020).","journal-title":"Mol. Oncol."},{"key":"627_CR28","doi-asserted-by":"crossref","unstructured":"John, A., O\u2019Sullivan, H. & Popat, S. Updates in Management of Malignant Pleural Mesothelioma. Curr. Treat. Options Oncol. (2023).","DOI":"10.1007\/s11864-023-01148-2"},{"key":"627_CR29","doi-asserted-by":"publisher","first-page":"100036","DOI":"10.1016\/j.modpat.2022.100036","volume":"36","author":"SD Martin","year":"2023","unstructured":"Martin, S. D., Cheung, S. & Churg, A. Immunohistochemical demonstration of Merlin\/NF2 loss in mesothelioma. Mod. Pathol. 36, 100036 (2023).","journal-title":"Mod. Pathol."},{"key":"627_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41586-021-03850-3","volume":"597","author":"F Nassiri","year":"2021","unstructured":"Nassiri, F. et al. A clinically applicable integrative molecular classification of meningiomas. Nature 597, 119\u2013125 (2021).","journal-title":"Nature"},{"key":"627_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/ijms22020690","volume":"22","author":"S Bachir","year":"2021","unstructured":"Bachir, S. et al. Neurofibromatosis Type 2 (NF2) and the implications for Vestibular Schwannoma and Meningioma pathogenesis. Int. J. Mol. Sci. 22, 690 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"627_CR32","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41431-021-01029-y","volume":"30","author":"D Moualed","year":"2022","unstructured":"Moualed, D. et al. Prevalence and natural history of schwannomas in neurofibromatosis type 2 (NF2): the influence of pathogenic variants. Eur. J. Hum. Genet. 30, 458\u2013464 (2022).","journal-title":"Eur. J. Hum. Genet."},{"key":"627_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","volume":"117","author":"MS Dirks","year":"2012","unstructured":"Dirks, M. S. et al. Long-term natural history of neurofibromatosis Type 2\u2013associated intracranial tumors: Clinical article. J. Neurosurg. 117, 109\u2013117 (2012).","journal-title":"J. Neurosurg."},{"key":"627_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05769-0","volume":"7","author":"H Chen","year":"2017","unstructured":"Chen, H., Xue, L., Wang, H., Wang, Z. & Wu, H. Differential NF2 gene status in sporadic vestibular schwannomas and its prognostic impact on tumour growth patterns. Sci. Rep. 7, 5470 (2017).","journal-title":"Sci. Rep."},{"key":"627_CR35","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin, S. R. et al. Multicenter, prospective, Phase II and biomarker study of high-dose Bevacizumab as induction therapy in patients with Neurofibromatosis Type 2 and progressive vestibular Schwannoma. J. Clin. Oncol.: J. Am. Soc. Clin. Oncol. 37, 3446\u20133454 (2019).","journal-title":"J. Clin. Oncol.: J. Am. Soc. Clin. Oncol."},{"key":"627_CR36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","volume":"124","author":"A Hochart","year":"2015","unstructured":"Hochart, A. et al. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J. Neuro-Oncol. 124, 229\u2013236 (2015).","journal-title":"J. Neuro-Oncol."},{"key":"627_CR37","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10014-017-0284-x","volume":"34","author":"R Tamura","year":"2017","unstructured":"Tamura, R., Tanaka, T., Miyake, K., Yoshida, K. & Sasaki, H. Bevacizumab for malignant gliomas: Current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol. 34, 62\u201377 (2017).","journal-title":"Brain Tumor Pathol."},{"key":"627_CR38","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.3390\/ijms23105462","volume":"23","author":"R Tamura","year":"2022","unstructured":"Tamura, R. & Toda, M. A critical overview of targeted therapies for vestibular Schwannoma. Int. J. Mol. Sci. 23, 5462 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"627_CR39","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/PAT.0b013e32834c3599","volume":"44","author":"NJ Yoo","year":"2012","unstructured":"Yoo, N. J., Park, S. W. & Lee, S. H. Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias. Pathology 44, 29\u201332 (2012).","journal-title":"Pathology"},{"key":"627_CR40","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.1133427","volume":"314","author":"T Sj\u00f6blom","year":"2006","unstructured":"Sj\u00f6blom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268\u2013274 (2006).","journal-title":"Science"},{"key":"627_CR41","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/ng0294-185","volume":"6","author":"AB Bianchi","year":"1994","unstructured":"Bianchi, A. B. et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat. Genet 6, 185\u2013192 (1994).","journal-title":"Nat. Genet"},{"key":"627_CR42","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","volume":"373","author":"AR Asthagiri","year":"2009","unstructured":"Asthagiri, A. R. et al. Neurofibromatosis type 2. Lancet 373, 1974\u20131986 (2009).","journal-title":"Lancet"},{"key":"627_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tcb.2007.03.006","volume":"17","author":"T Okada","year":"2007","unstructured":"Okada, T., You, L. & Giancotti, F. G. Shedding light on Merlin\u2019s wizardry. Trends Cell Biol. 17, 222\u2013229 (2007).","journal-title":"Trends Cell Biol."},{"key":"627_CR44","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41556-018-0142-z","volume":"20","author":"A Totaro","year":"2018","unstructured":"Totaro, A., Panciera, T. & Piccolo, S. YAP\/TAZ upstream signals and downstream responses. Nat. Cell Biol. 20, 888\u2013899 (2018).","journal-title":"Nat. Cell Biol."},{"key":"627_CR45","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2013.08.025","volume":"154","author":"F Yin","year":"2013","unstructured":"Yin, F. et al. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin\/NF2. Cell 154, 1342\u20131355 (2013).","journal-title":"Cell"},{"key":"627_CR46","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","volume":"19","author":"A Dey","year":"2020","unstructured":"Dey, A., Varelas, X. & Guan, K.-L. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat. Rev. Drug Discov. 19, 480\u2013494 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"627_CR47","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3390\/cancers13071561","volume":"13","author":"H Yang","year":"2021","unstructured":"Yang, H. et al. NF2 and canonical Hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural Mesothelioma. Cancers 13, 1561 (2021).","journal-title":"Cancers"},{"key":"627_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9357","volume":"6","author":"Z Meng","year":"2015","unstructured":"Meng, Z. et al. MAP4K family kinases act in parallel to MST1\/2 to activate LATS1\/2 in the Hippo pathway. Nat. Commun. 6, 8357 (2015).","journal-title":"Nat. Commun."},{"key":"627_CR49","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2022112126","volume":"42","author":"S Qi","year":"2023","unstructured":"Qi, S. et al. Two Hippo signaling modules orchestrate liver size and tumorigenesis. EMBO J. 42, e112126 (2023).","journal-title":"EMBO J."},{"key":"627_CR50","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1158\/1541-7786.MCR-19-0914","volume":"18","author":"S Kandasamy","year":"2020","unstructured":"Kandasamy, S. et al. The YAP1 signaling inhibitors, Verteporfin and CA3, suppress the mesothelioma cancer stem cell phenotype. Mol. Cancer Res. 18, 343\u2013351 (2020).","journal-title":"Mol. Cancer Res."},{"key":"627_CR51","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1007\/s10072-021-05193-3","volume":"42","author":"KHD Ignacio","year":"2021","unstructured":"Ignacio, K. H. D. et al. Efficacy of aspirin for sporadic vestibular schwannoma: a meta-analysis. Neurological Sci. 42, 5101\u20135106 (2021).","journal-title":"Neurological Sci."},{"key":"627_CR52","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1227\/NEU.0b013e318208f5c7","volume":"68","author":"B Hong","year":"2011","unstructured":"Hong, B. et al. Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas. Neurosurgery 68, 1112\u20131117 (2011).","journal-title":"Neurosurgery"},{"key":"627_CR53","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.3390\/ijms20153821","volume":"20","author":"P-C Hsu","year":"2019","unstructured":"Hsu, P.-C., Jablons, D. M., Yang, C.-T. & You, L. Epidermal Growth Factor Receptor (EGFR) pathway, Yes-Associated Protein (YAP) and the regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 20, 3821 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"627_CR54","doi-asserted-by":"publisher","first-page":"eaaz4589","DOI":"10.1126\/scitranslmed.aaz4589","volume":"12","author":"MB Nilsson","year":"2020","unstructured":"Nilsson, M. B. et al. A YAP\/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Sci. Transl. Med 12, eaaz4589 (2020).","journal-title":"Sci. Transl. Med"},{"key":"627_CR55","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2559.2009.03440.x","volume":"55","author":"DA Hilton","year":"2009","unstructured":"Hilton, D. A., Ristic, N. & Hanemann, C. O. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 55, 744\u2013749 (2009).","journal-title":"Histopathology"},{"key":"627_CR56","doi-asserted-by":"publisher","first-page":"18200","DOI":"10.1073\/pnas.0405971102","volume":"101","author":"R Rong","year":"2004","unstructured":"Rong, R., Tang, X., Gutmann, D. H. & Ye, K. Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L. Proc. Natl Acad. Sci. 101, 18200\u201318205 (2004).","journal-title":"Proc. Natl Acad. Sci."},{"key":"627_CR57","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1006\/mcne.2000.0967","volume":"17","author":"Y Li","year":"2001","unstructured":"Li, Y., Tennekoon, G. I., Birnbaum, M., Marchionni, M. A. & Rutkowski, J. L. Neuregulin signaling through a PI3K\/Akt\/Bad Pathway in Schwann cell survival. Mol. Cell. Neurosci. 17, 761\u2013767 (2001).","journal-title":"Mol. Cell. Neurosci."},{"key":"627_CR58","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1158\/0008-5472.CAN-08-3931","volume":"69","author":"M Okada","year":"2009","unstructured":"Okada, M. et al. Akt phosphorylation of merlin enhances its binding to phosphatidylinositols and inhibits the tumor-suppressive activities of Merlin. Cancer Res. 69, 4043\u20134051 (2009).","journal-title":"Cancer Res."},{"key":"627_CR59","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.1128\/MCB.01578-08","volume":"29","author":"MA L\u00f3pez-Lago","year":"2009","unstructured":"L\u00f3pez-Lago, M. A., Okada, T., Murillo, M. M., Socci, N. & Giancotti, F. G. Loss of the tumor suppressor Gene NF2, encoding Merlin, constitutively activates Integrin-dependent mTORC1 signaling. Mol. Cell. Biol. 29, 4235\u20134249 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"627_CR60","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James, M. F. et al. NF2\/Merlin is a novel negative regulator of mTOR Complex 1, and activation of mTORC1 is associated with Meningioma and Schwannoma growth. Mol. Cell. Biol. 29, 4250\u20134261 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"627_CR61","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41586-019-1426-6","volume":"572","author":"J Wu","year":"2019","unstructured":"Wu, J. et al. Intercellular interaction dictates cancer cell ferroptosis via NF2\u2013YAP signalling. Nature 572, 402\u2013406 (2019).","journal-title":"Nature"},{"key":"627_CR62","doi-asserted-by":"publisher","first-page":"42590","DOI":"10.18632\/oncotarget.6052","volume":"6","author":"Y Sang","year":"2015","unstructured":"Sang, Y., Yan, F. & Ren, X. The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications. Oncotarget 6, 42590\u201342602 (2015).","journal-title":"Oncotarget"},{"key":"627_CR63","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/ncb2634","volume":"14","author":"A Csibi","year":"2012","unstructured":"Csibi, A. & Blenis, J. Hippo\u2013YAP and mTOR pathways collaborate to regulate organ size. Nat. Cell Biol. 14, 1244\u20131245 (2012).","journal-title":"Nat. Cell Biol."},{"key":"627_CR64","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41388-024-02958-w","volume":"43","author":"A Nagel","year":"2024","unstructured":"Nagel, A. et al. Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis. Oncogene 43, 921\u2013930 (2024).","journal-title":"Oncogene"},{"key":"627_CR65","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1126\/science.1715094","volume":"253","author":"J Heitman","year":"1991","unstructured":"Heitman, J., Movva, N. R. & Hall, M. N. Targets for cell cycle arrest by the immunosuppressant Rapamycin in yeast. Science 253, 905\u2013909 (1991).","journal-title":"Science"},{"key":"627_CR66","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/neuonc\/not150","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis, M. A. et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro-Oncol. 16, 292\u2013297 (2014).","journal-title":"Neuro-Oncol."},{"key":"627_CR67","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny, S. et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J. Neurooncol 122, 313\u2013320 (2015).","journal-title":"J. Neurooncol"},{"key":"627_CR68","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/JTO.0000000000000360","volume":"10","author":"S-HI Ou","year":"2015","unstructured":"Ou, S.-H. I. et al. SWOG S0722: Phase II study of mTOR Inhibitor Everolimus (RAD001) in advanced Malignant Pleural Mesothelioma (MPM). J. Thorac. Oncol. 10, 387\u2013391 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"627_CR69","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s10637-021-01086-6","volume":"39","author":"MG Zauderer","year":"2021","unstructured":"Zauderer, M. G. et al. Phase 1 cohort expansion study of LY3023414, a dual PI3K\/mTOR inhibitor, in patients with advanced mesothelioma. Invest N. Drugs 39, 1081\u20131088 (2021).","journal-title":"Invest N. Drugs"},{"key":"627_CR70","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","volume":"67","author":"H Morrison","year":"2007","unstructured":"Morrison, H. et al. Merlin\/Neurofibromatosis Type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 67, 520\u2013527 (2007).","journal-title":"Cancer Res."},{"key":"627_CR71","doi-asserted-by":"publisher","first-page":"23387","DOI":"10.1016\/S0021-9258(17)31525-9","volume":"269","author":"A Tikoo","year":"1994","unstructured":"Tikoo, A., Varga, M., Ramesh, V., Gusella, J. & Maruta, H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2\/Merlin). J. Biol. Chem. 269, 23387\u201323390 (1994).","journal-title":"J. Biol. Chem."},{"key":"627_CR72","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1038\/s41388-019-0883-6","volume":"38","author":"Y Cui","year":"2019","unstructured":"Cui, Y. et al. The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling. Oncogene 38, 6370\u20136381 (2019).","journal-title":"Oncogene"},{"key":"627_CR73","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1158\/2159-8290.CD-15-0330","volume":"5","author":"ME Garcia-Rendueles","year":"2015","unstructured":"Garcia-Rendueles, M. E. et al. NF2 loss promotes Oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK Inhibition. Cancer Discov. 5, 1178\u20131193 (2015).","journal-title":"Cancer Discov."},{"key":"627_CR74","doi-asserted-by":"publisher","first-page":"10394","DOI":"10.1074\/jbc.M200083200","volume":"277","author":"JL Kissil","year":"2002","unstructured":"Kissil, J. L., Johnson, K. C., Eckman, M. S. & Jacks, T. Merlin Phosphorylation by p21-activated Kinase 2 and effects of phosphorylation on merlin localization. J. Biol. Chem. 277, 10394\u201310399 (2002).","journal-title":"J. Biol. Chem."},{"key":"627_CR75","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1097-2765(03)00382-4","volume":"12","author":"JL Kissil","year":"2003","unstructured":"Kissil, J. L. et al. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated Kinase, Pak1. Mol. Cell 12, 841\u2013849 (2003).","journal-title":"Mol. Cell"},{"key":"627_CR76","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1128\/MCB.25.6.2384-2394.2005","volume":"25","author":"G-H Xiao","year":"2005","unstructured":"Xiao, G.-H. et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing Cyclin D1 Expression. Mol. Cell. Biol. 25, 2384\u20132394 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"627_CR77","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.molcel.2011.10.016","volume":"44","author":"D Matallanas","year":"2011","unstructured":"Matallanas, D. et al. Mutant K-Ras activation of the Proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol. Cell 44, 893\u2013906 (2011).","journal-title":"Mol. Cell"},{"key":"627_CR78","doi-asserted-by":"publisher","first-page":"e13631","DOI":"10.15252\/emmm.202013631","volume":"14","author":"A Marazioti","year":"2022","unstructured":"Marazioti, A. et al. KRAS signaling in malignant pleural mesothelioma. EMBO Mol. Med. 14, e13631 (2022).","journal-title":"EMBO Mol. Med."},{"key":"627_CR79","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","volume":"5","author":"S Dubey","year":"2010","unstructured":"Dubey, S. et al. A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J. Thorac. Oncol. 5, 1655\u20131661 (2010).","journal-title":"J. Thorac. Oncol."},{"key":"627_CR80","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"A Sacher","year":"2023","unstructured":"Sacher, A. et al. Single-agent Divarasib (GDC-6036) in solid tumors with a KRAS G12C mutation. N. Engl. J. Med 389, 710\u2013721 (2023).","journal-title":"N. Engl. J. Med"},{"key":"627_CR81","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS(G12C) inhibition with Sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."},{"key":"627_CR82","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160\u2013166 (2023).","journal-title":"Nature"},{"key":"627_CR83","doi-asserted-by":"publisher","first-page":"5960","DOI":"10.1038\/sj.onc.1209587","volume":"25","author":"PI Poulikakos","year":"2006","unstructured":"Poulikakos, P. I. et al. Re-expression of the tumor suppressor NF2\/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 25, 5960\u20135968 (2006).","journal-title":"Oncogene"},{"key":"627_CR84","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1093\/annonc\/mdw427","volume":"27","author":"JC Soria","year":"2016","unstructured":"Soria, J. C. et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann. Oncol.: J. Eur. Soc. Med. Oncol. 27, 2268\u20132274 (2016).","journal-title":"Ann. Oncol.: J. Eur. Soc. Med. Oncol."},{"key":"627_CR85","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","volume":"37","author":"DA Fennell","year":"2019","unstructured":"Fennell, D. A. et al. Maintenance Defactinib versus placebo after first-line chemotherapy in patients with merlin-stratified pleural Mesothelioma: COMMAND\u2014A double-blind, randomized, Phase II study. J. Clin. Oncol. 37, 790\u2013798 (2019).","journal-title":"J. Clin. Oncol."},{"key":"627_CR86","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.stem.2014.10.016","volume":"15","author":"S-K Kim","year":"2014","unstructured":"Kim, S.-K. et al. SET7\/9 methylation of the Pluripotency Factor LIN28A is a nucleolar localization mechanism that blocks let-7 biogenesis in human ESCs. Cell Stem Cell 15, 735\u2013749 (2014).","journal-title":"Cell Stem Cell"},{"key":"627_CR87","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.celrep.2016.02.075","volume":"14","author":"H Hikasa","year":"2016","unstructured":"Hikasa, H., Sekido, Y. & Suzuki, A. Merlin\/NF2-Lin28B-let-7 is a tumor-suppressive pathway that is cell-density dependent and Hippo independent. Cell Rep. 14, 2950\u20132961 (2016).","journal-title":"Cell Rep."},{"key":"627_CR88","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","volume":"120","author":"SM Johnson","year":"2005","unstructured":"Johnson, S. M. et al. RAS is regulated by the let-7 MicroRNA Family. Cell 120, 635\u2013647 (2005).","journal-title":"Cell"},{"key":"627_CR89","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/ng2003","volume":"39","author":"MS Kumar","year":"2007","unstructured":"Kumar, M. S., Lu, J., Mercer, K. L., Golub, T. R. & Jacks, T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat. Genet. 39, 673\u2013677 (2007).","journal-title":"Nat. Genet."},{"key":"627_CR90","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin, S. R. et al. Erlotinib for progressive vestibular Schwannoma in Neurofibromatosis 2 patients. Otol. Neurotol. 31, 1135\u20131143 (2010).","journal-title":"Otol. Neurotol."},{"key":"627_CR91","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1200\/JCO.2006.09.7634","volume":"25","author":"LL Garland","year":"2007","unstructured":"Garland, L. L. et al. Phase II Study of Erlotinib in patients with malignant pleural mesothelioma: A Southwest Oncology Group Study. J. Clin. Oncol. 25, 2406\u20132413 (2007).","journal-title":"J. Clin. Oncol."},{"key":"627_CR92","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3171\/2022.9.JNS22699","volume":"138","author":"F Zhao","year":"2023","unstructured":"Zhao, F. et al. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma. J. Neurosurg. 138, 1680\u20131687 (2023).","journal-title":"J. Neurosurg."},{"key":"627_CR93","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1158\/1078-0432.CCR-04-1940","volume":"11","author":"R Govindan","year":"2005","unstructured":"Govindan, R. et al. Gefitinib in patients with malignant Mesothelioma: A Phase II study by the cancer and leukemia Group B. Clin. Cancer Res. 11, 2300\u20132304 (2005).","journal-title":"Clin. Cancer Res."},{"key":"627_CR94","doi-asserted-by":"publisher","first-page":"e20030","DOI":"10.1200\/JCO.2017.35.15_suppl.e20030","volume":"35","author":"AD Paepe","year":"2017","unstructured":"Paepe, A. D. et al. Cetuximab plus platinum-based chemotherapy in patients with malignant pleural mesothelioma: A single arm phase II trial. J. Clin. Oncol. 35, e20030\u2013e20030 (2017).","journal-title":"J. Clin. Oncol."},{"key":"627_CR95","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.trecan.2021.04.009","volume":"7","author":"G El Tekle","year":"2021","unstructured":"El Tekle, G. et al. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends Cancer 7, 823\u2013836 (2021).","journal-title":"Trends Cancer"},{"key":"627_CR96","doi-asserted-by":"publisher","first-page":"4264","DOI":"10.1038\/onc.2012.436","volume":"32","author":"M Peyre","year":"2013","unstructured":"Peyre, M. et al. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene 32, 4264\u20134272 (2013).","journal-title":"Oncogene"},{"key":"627_CR97","doi-asserted-by":"publisher","first-page":"32713","DOI":"10.18632\/oncotarget.5296","volume":"6","author":"M Peyre","year":"2015","unstructured":"Peyre, M. et al. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget 6, 32713\u201332722 (2015).","journal-title":"Oncotarget"},{"key":"627_CR98","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/modpathol.2015.121","volume":"29","author":"AD Singhi","year":"2016","unstructured":"Singhi, A. D. et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod. Pathol. 29, 14\u201324 (2016).","journal-title":"Mod. Pathol."},{"key":"627_CR99","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.3390\/cancers14225626","volume":"14","author":"HU Osmanbeyoglu","year":"2022","unstructured":"Osmanbeyoglu, H. U. et al. Isolated BAP1 genomic alteration in malignant Pleural Mesothelioma predicts distinct immunogenicity with implications for immunotherapeutic response. Cancers 14, 5626 (2022).","journal-title":"Cancers"},{"key":"627_CR100","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s12276-023-00979-1","volume":"55","author":"J Kwon","year":"2023","unstructured":"Kwon, J., Lee, D. & Lee, S. A. BAP1 as a guardian of genome stability: Implications in human cancer. Exp. Mol. Med 55, 745\u2013754 (2023).","journal-title":"Exp. Mol. Med"},{"key":"627_CR101","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"Yap, T. A., Aerts, J. G., Popat, S. & Fennell, D. A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer 17, 475\u2013488 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"627_CR102","doi-asserted-by":"publisher","first-page":"e20191257","DOI":"10.1084\/jem.20191257","volume":"217","author":"J Badhai","year":"2020","unstructured":"Badhai, J. et al. Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice. J. Exp. Med. 217, e20191257 (2020).","journal-title":"J. Exp. Med."},{"key":"627_CR103","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.1158\/0008-5472.CAN-18-4093","volume":"79","author":"AM Kukuyan","year":"2019","unstructured":"Kukuyan, A. M. et al. Inactivation of Bap1 cooperates with losses of Nf2 and Cdkn2a to drive the development of pleural malignant mesothelioma in conditional mouse models. Cancer Res 79, 4113\u20134123 (2019).","journal-title":"Cancer Res"},{"key":"627_CR104","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1158\/1078-0432.CCR-16-1971","volume":"23","author":"R Tranchant","year":"2017","unstructured":"Tranchant, R. et al. Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin. Cancer Res. 23, 3191\u20133202 (2017).","journal-title":"Clin. Cancer Res."},{"key":"627_CR105","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41556-020-0463-6","volume":"22","author":"W Gan","year":"2020","unstructured":"Gan, W. et al. LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat. Cell Biol. 22, 246\u2013256 (2020).","journal-title":"Nat. Cell Biol."},{"key":"627_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.116553","volume":"408","author":"N Waldt","year":"2020","unstructured":"Waldt, N. et al. Loss of PTPRJ\/DEP-1 enhances NF2\/Merlin-dependent meningioma development. J. Neurol. Sci. 408, 116553 (2020).","journal-title":"J. Neurol. Sci."},{"key":"627_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh, S., Gro\u00df, O., Brummer, T. & Zeiser, R. Immune modulatory effects of oncogenic KRAS in cancer. Nat. Commun. 11, 5439 (2020).","journal-title":"Nat. Commun."},{"key":"627_CR108","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","volume":"78","author":"P Dias Carvalho","year":"2018","unstructured":"Dias Carvalho, P. et al. KRAS oncogenic signaling extends beyond cancer cells to orchestrate the microenvironment. Cancer Res 78, 7\u201314 (2018).","journal-title":"Cancer Res"},{"key":"627_CR109","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F. & Fu, L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct. Target Ther. 6, 386 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"627_CR110","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00401-013-1093-x","volume":"125","author":"DE Reuss","year":"2013","unstructured":"Reuss, D. E. et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol. 125, 351\u2013358 (2013).","journal-title":"Acta Neuropathol."},{"key":"627_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1750-3639.2006.tb00557.x","volume":"16","author":"C Hartmann","year":"2006","unstructured":"Hartmann, C. et al. NF2 mutations in secretory and other rare variants of meningiomas. Brain Pathol. 16, 15\u201319 (2006).","journal-title":"Brain Pathol."},{"key":"627_CR112","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s40478-019-0793-4","volume":"7","author":"G Jungwirth","year":"2019","unstructured":"Jungwirth, G. et al. Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. Acta Neuropathol. Commun. 7, 140 (2019).","journal-title":"Acta Neuropathol. Commun."},{"key":"627_CR113","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1126\/science.1233009","volume":"339","author":"VE Clark","year":"2013","unstructured":"Clark, V. E. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077\u20131080 (2013).","journal-title":"Science"},{"key":"627_CR114","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"627_CR115","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"627_CR116","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbcan.2018.06.005","volume":"1870","author":"L Sun","year":"2018","unstructured":"Sun, L., Suo, C., Li, S. T., Zhang, H. & Gao, P. Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys. Acta Rev. Cancer 1870, 51\u201366 (2018).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"627_CR117","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"K Birsoy","year":"2015","unstructured":"Birsoy, K. et al. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable Aspartate synthesis. Cell 162, 540\u2013551 (2015).","journal-title":"Cell"},{"key":"627_CR118","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.molcel.2020.12.012","volume":"81","author":"A Luengo","year":"2021","unstructured":"Luengo, A. et al. Increased demand for NAD(+) relative to ATP drives aerobic glycolysis. Mol. Cell 81, 691\u2013707.e696 (2021).","journal-title":"Mol. Cell"},{"key":"627_CR119","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.1158\/0008-5472.CAN-16-2834","volume":"77","author":"DS Stepanova","year":"2017","unstructured":"Stepanova, D. S. et al. An essential role for the tumor-suppressor Merlin in regulating fatty acid synthesis. Cancer Res. 77, 5026\u20135038 (2017).","journal-title":"Cancer Res."},{"key":"627_CR120","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1016\/j.molcel.2021.07.040","volume":"81","author":"F Meng","year":"2021","unstructured":"Meng, F. et al. Induced phase separation of mutant NF2 imprisons the cGAS-STING machinery to abrogate antitumor immunity. Mol. Cell 81, 4147\u20134164.e4147 (2021).","journal-title":"Mol. Cell"},{"key":"627_CR121","doi-asserted-by":"crossref","unstructured":"Magaway, C., Kim, E. & Jacinto, E. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations. Cells 8, (2019).","DOI":"10.3390\/cells8121584"},{"key":"627_CR122","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.trecan.2016.06.002","volume":"2","author":"A Nagarajan","year":"2016","unstructured":"Nagarajan, A., Malvi, P. & Wajapeyee, N. Oncogene-directed alterations in cancer cell metabolism. Trends Cancer 2, 365\u2013377 (2016).","journal-title":"Trends Cancer"},{"key":"627_CR123","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.tem.2018.04.006","volume":"29","author":"A Ardestani","year":"2018","unstructured":"Ardestani, A., Lupse, B. & Maedler, K. Hippo signaling: key emerging pathway in cellular and whole-body metabolism. Trends Endocrinol. Metab. 29, 492\u2013509 (2018).","journal-title":"Trends Endocrinol. Metab."},{"key":"627_CR124","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.devcel.2019.04.014","volume":"49","author":"SM White","year":"2019","unstructured":"White, S. M. et al. YAP\/TAZ inhibition induces metabolic and signaling rewiring resulting in targetable vulnerabilities in NF2-deficient tumor cells. Dev. Cell 49, 425\u2013443.e429 (2019).","journal-title":"Dev. Cell"},{"key":"627_CR125","doi-asserted-by":"publisher","first-page":"9877","DOI":"10.1073\/pnas.1819400116","volume":"116","author":"NG Kim","year":"2019","unstructured":"Kim, N. G. & Gumbiner, B. M. Cell contact and Nf2\/Merlin-dependent regulation of TEAD palmitoylation and activity. Proc. Natl Acad. Sci. USA 116, 9877\u20139882 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR126","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/17460441.2016.1245286","volume":"11","author":"TS Angeles","year":"2016","unstructured":"Angeles, T. S. & Hudkins, R. L. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert Opin. Drug Discov. 11, 1187\u20131199 (2016).","journal-title":"Expert Opin. Drug Discov."},{"key":"627_CR127","first-page":"153","volume":"7","author":"EW Gabrielson","year":"2001","unstructured":"Gabrielson, E. W., Pinn, M. L., Testa, J. R. & Kuhajda, F. P. Increased fatty acid synthase is a therapeutic target in mesothelioma. Clin. Cancer Res. 7, 153\u2013157 (2001).","journal-title":"Clin. Cancer Res."},{"key":"627_CR128","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1016\/j.jss.2011.06.037","volume":"170","author":"K Asakura","year":"2011","unstructured":"Asakura, K. et al. The cytostatic effects of lovastatin on ACC-MESO-1 cells. J. Surg. Res. 170, e197\u2013e209 (2011).","journal-title":"J. Surg. Res."},{"key":"627_CR129","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.canlet.2016.10.020","volume":"385","author":"K Tanaka","year":"2017","unstructured":"Tanaka, K. et al. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP\/CD44 growth stimulatory axis. Cancer Lett. 385, 215\u2013224 (2017).","journal-title":"Cancer Lett."},{"key":"627_CR130","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1164\/ajrccm.157.5.9709020","volume":"157","author":"JB Rubins","year":"1998","unstructured":"Rubins, J. B. et al. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 157, 1616\u20131622 (1998).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"627_CR131","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41571-020-00462-0","volume":"18","author":"X Chen","year":"2021","unstructured":"Chen, X., Kang, R., Kroemer, G. & Tang, D. Broadening horizons: the role of ferroptosis in cancer. Nat. Rev. Clin. Oncol. 18, 280\u2013296 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"627_CR132","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57\u201362 (2015).","journal-title":"Nature"},{"key":"627_CR133","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/s41556-018-0178-0","volume":"20","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol. 20, 1181\u20131192 (2018).","journal-title":"Nat. Cell Biol."},{"key":"627_CR134","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1080\/15548627.2022.2062875","volume":"18","author":"C Bodineau","year":"2022","unstructured":"Bodineau, C., Tom\u00e9, M., Murdoch, P. D. S. & Dur\u00e1n, R. V. Glutamine, MTOR and autophagy: a multiconnection relationship. Autophagy 18, 2749\u20132750 (2022).","journal-title":"Autophagy"},{"key":"627_CR135","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.molcel.2012.05.043","volume":"47","author":"RV Dur\u00e1n","year":"2012","unstructured":"Dur\u00e1n, R. V. et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol. Cell 47, 349\u2013358 (2012).","journal-title":"Mol. Cell"},{"key":"627_CR136","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/msb.2011.56","volume":"7","author":"D Gaglio","year":"2011","unstructured":"Gaglio, D. et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol. Syst. Biol. 7, 523 (2011).","journal-title":"Mol. Syst. Biol."},{"key":"627_CR137","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nature12138","volume":"497","author":"C Commisso","year":"2013","unstructured":"Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633\u2013637 (2013).","journal-title":"Nature"},{"key":"627_CR138","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1101\/gad.317354.118","volume":"32","author":"C Chiasson-MacKenzie","year":"2018","unstructured":"Chiasson-MacKenzie, C. et al. Merlin\/ERM proteins regulate growth factor-induced macropinocytosis and receptor recycling by organizing the plasma membrane:cytoskeleton interface. Genes Dev. 32, 1201\u20131214 (2018).","journal-title":"Genes Dev."},{"key":"627_CR139","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-021-00375-9","volume":"21","author":"SA Kerk","year":"2021","unstructured":"Kerk, S. A., Papagiannakopoulos, T., Shah, Y. M. & Lyssiotis, C. A. Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment. Nat. Rev. Cancer 21, 510\u2013525 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"627_CR140","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/ajmg.a.36312","volume":"164a","author":"BC Widemann","year":"2014","unstructured":"Widemann, B. C. et al. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am. J. Med Genet A 164a, 563\u2013578 (2014).","journal-title":"Am. J. Med Genet A"},{"key":"627_CR141","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","volume":"2","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay, S., Vander Heiden, M. G. & McCormick, F. The metabolic landscape of RAS-driven cancers from biology to therapy. Nat. Cancer 2, 271\u2013283 (2021).","journal-title":"Nat. Cancer"},{"key":"627_CR142","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cmet.2016.10.011","volume":"24","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Targeting stromal glutamine synthetase in tumors disrupts tumor microenvironment-regulated cancer cell growth. Cell Metab. 24, 685\u2013700 (2016).","journal-title":"Cell Metab."},{"key":"627_CR143","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41580-020-00313-x","volume":"22","author":"AJ Covarrubias","year":"2021","unstructured":"Covarrubias, A. J., Perrone, R., Grozio, A. & Verdin, E. NAD(+) metabolism and its roles in cellular processes during ageing. Nat. Rev. Mol. Cell Biol. 22, 119\u2013141 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"627_CR144","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.18632\/oncotarget.1422","volume":"4","author":"A Petrilli","year":"2013","unstructured":"Petrilli, A., Bott, M. & Fern\u00e1ndez-Valle, C. Inhibition of SIRT2 in merlin\/NF2-mutant Schwann cells triggers necrosis. Oncotarget 4, 2354\u20132365 (2013).","journal-title":"Oncotarget"},{"key":"627_CR145","doi-asserted-by":"publisher","first-page":"7490","DOI":"10.1074\/jbc.TM117.000239","volume":"293","author":"AM Hosios","year":"2018","unstructured":"Hosios, A. M. & Vander Heiden, M. G. The redox requirements of proliferating mammalian cells. J. Biol. Chem. 293, 7490\u20137498 (2018).","journal-title":"J. Biol. Chem."},{"key":"627_CR146","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41556-018-0118-z","volume":"20","author":"J Garcia-Bermudez","year":"2018","unstructured":"Garcia-Bermudez, J. et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 20, 775\u2013781 (2018).","journal-title":"Nat. Cell Biol."},{"key":"627_CR147","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41568-023-00557-7","volume":"23","author":"NJ Mullen","year":"2023","unstructured":"Mullen, N. J. & Singh, P. K. Nucleotide metabolism: a pan-cancer metabolic dependency. Nat. Rev. Cancer 23, 275\u2013294 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"627_CR148","first-page":"1","volume":"33","author":"S Beltrami","year":"2013","unstructured":"Beltrami, S., Kim, R. & Gordon, J. Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator. Anticancer Res 33, 1\u201311 (2013).","journal-title":"Anticancer Res"},{"key":"627_CR149","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.devcel.2022.02.024","volume":"57","author":"J Simcox","year":"2022","unstructured":"Simcox, J. & Lamming, D. W. The central moTOR of metabolism. Dev. Cell 57, 691\u2013706 (2022).","journal-title":"Dev. Cell"},{"key":"627_CR150","first-page":"S391","volume":"18","author":"D Xu","year":"2023","unstructured":"Xu, D., Schmid, R. A., Peng, R. W. & Shu, Y. P2.21-08 Mutant NF2-Driven De Novo Pyrimidine synthesis is a metabolic vulnerability in malignant pleural Mesothelioma. J. Thoracic Oncol. 18, S391 (2023).","journal-title":"J. Thoracic Oncol."},{"key":"627_CR151","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-018-2788-6","volume":"138","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. J. Neuro-Oncol. 138, 183\u2013190 (2018).","journal-title":"J. Neuro-Oncol."},{"key":"627_CR152","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"627_CR153","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06231-0","volume":"619","author":"L Bod","year":"2023","unstructured":"Bod, L. et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature 619, 348\u2013356 (2023).","journal-title":"Nature"},{"key":"627_CR154","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/annonc\/mdy086","volume":"29","author":"G Pasello","year":"2018","unstructured":"Pasello, G. et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann. Oncol. 29, 1258\u20131265 (2018).","journal-title":"Ann. Oncol."},{"key":"627_CR155","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207\u2013212 (2012).","journal-title":"Curr. Opin. Immunol."},{"key":"627_CR156","doi-asserted-by":"publisher","first-page":"20321","DOI":"10.1073\/pnas.0810773105","volume":"105","author":"D Zhou","year":"2008","unstructured":"Zhou, D. et al. The Nore1B\/Mst1 complex restrains antigen receptor-induced proliferation of na\u00efve T cells. Proc. Natl Acad. Sci. 105, 20321\u201320326 (2008).","journal-title":"Proc. Natl Acad. Sci."},{"key":"627_CR157","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1084\/jem.20111692","volume":"209","author":"F Mou","year":"2012","unstructured":"Mou, F. et al. The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J. Exp. Med. 209, 741\u2013759 (2012).","journal-title":"J. Exp. Med."},{"key":"627_CR158","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","volume":"167","author":"T Moroishi","year":"2016","unstructured":"Moroishi, T. et al. The Hippo Pathway Kinases LATS1\/2 suppress cancer immunity. Cell 167, 1525\u20131539.e1517 (2016).","journal-title":"Cell"},{"key":"627_CR159","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","volume":"14","author":"LB Ivashkiv","year":"2014","unstructured":"Ivashkiv, L. B. & Donlin, L. T. Regulation of type I interferon responses. Nat. Rev. Immunol. 14, 36\u201349 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"627_CR160","doi-asserted-by":"publisher","first-page":"15408","DOI":"10.1073\/pnas.1512832112","volume":"112","author":"O Demaria","year":"2015","unstructured":"Demaria, O. et al. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 112, 15408\u201315413 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"627_CR161","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/cr.2016.149","volume":"27","author":"L Corrales","year":"2017","unstructured":"Corrales, L., Matson, V., Flood, B., Spranger, S. & Gajewski, T. F. Innate immune signaling and regulation in cancer immunotherapy. Cell Res 27, 96\u2013108 (2017).","journal-title":"Cell Res"},{"key":"627_CR162","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2016.12.005","volume":"45","author":"J Qiao","year":"2017","unstructured":"Qiao, J., Tang, H. & Fu, Y.-X. DNA sensing and immune responses in cancer therapy. Curr. Opin. Immunol. 45, 16\u201320 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"627_CR163","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","volume":"48","author":"JS O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell, J. S., Massi, D., Teng, M. W. L. & Mandala, M. PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. Semin. Cancer Biol. 48, 91\u2013103 (2018).","journal-title":"Semin. Cancer Biol."},{"key":"627_CR164","doi-asserted-by":"publisher","first-page":"e95103","DOI":"10.1172\/jci.insight.95103","volume":"2","author":"CA Klebanoff","year":"2017","unstructured":"Klebanoff, C. A. et al. Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight 2, e95103 (2017).","journal-title":"JCI Insight"},{"key":"627_CR165","unstructured":"PI3K and AKT Isoforms in Immunity: Mechanisms and Therapeutic Opportunities, (Springer International Publishing, Cham, 2022)."},{"key":"627_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04486-9","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu, Y., Xie, B. & Chen, Q. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment. J. Transl. Med. 21, 595 (2023).","journal-title":"J. Transl. Med."},{"key":"627_CR167","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri.2016.99","volume":"16","author":"C Mu\u00f1oz-Fontela","year":"2016","unstructured":"Mu\u00f1oz-Fontela, C., Mandinova, A., Aaronson, S. A. & Lee, S. W. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat. Rev. Immunol. 16, 741\u2013750 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"627_CR168","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).","journal-title":"Sci. Adv."},{"key":"627_CR169","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1158\/2159-8290.CD-20-1211","volume":"11","author":"P Dey","year":"2021","unstructured":"Dey, P., Kimmelman, A. C. & DePinho, R. A. Metabolic codependencies in the tumor microenvironment. Cancer Discov. 11, 1067\u20131081 (2021).","journal-title":"Cancer Discov."},{"key":"627_CR170","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie, E., Schulze, A., Zechner, R., Walther, T. C. & Farese, R. V. Jr. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153\u2013161 (2013).","journal-title":"Cell Metab."},{"key":"627_CR171","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.bbrc.2019.01.090","volume":"510","author":"Q Wen","year":"2019","unstructured":"Wen, Q., Liu, J., Kang, R., Zhou, B. & Tang, D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 510, 278\u2013283 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"627_CR172","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1080\/15548627.2020.1714209","volume":"16","author":"E Dai","year":"2020","unstructured":"Dai, E. et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy 16, 2069\u20132083 (2020).","journal-title":"Autophagy"},{"key":"627_CR173","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang, W. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270\u2013274 (2019).","journal-title":"Nature"},{"key":"627_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01316-8","volume":"20","author":"L Xia","year":"2021","unstructured":"Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20, 28 (2021).","journal-title":"Mol. Cancer"},{"key":"627_CR175","doi-asserted-by":"publisher","first-page":"e103009","DOI":"10.15252\/embj.2019103009","volume":"39","author":"SJ Fan","year":"2020","unstructured":"Fan, S. J. et al. Glutamine deprivation alters the origin and function of cancer cell exosomes. EMBO J. 39, e103009 (2020).","journal-title":"EMBO J."},{"key":"627_CR176","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine, Z. E., Schug, Z. T., Salvino, J. M. & Dang, C. V. Targeting cancer metabolism in the era of precision oncology. Nat. Rev. Drug Discov. 21, 141\u2013162 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"627_CR177","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","volume":"620","author":"C Guo","year":"2023","unstructured":"Guo, C. et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature 620, 200\u2013208 (2023).","journal-title":"Nature"},{"key":"627_CR178","doi-asserted-by":"publisher","first-page":"103008","DOI":"10.1016\/j.copbio.2023.103008","volume":"84","author":"HB Madsen","year":"2023","unstructured":"Madsen, H. B., Peeters, M. J., Straten, P. T. & Desler, C. Nucleotide metabolism in the regulation of tumor microenvironment and immune cell function. Curr. Opin. Biotechnol. 84, 103008 (2023).","journal-title":"Curr. Opin. Biotechnol."},{"key":"627_CR179","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/nar\/gkv047","volume":"43","author":"AN Lane","year":"2015","unstructured":"Lane, A. N. & Fan, T. W. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res 43, 2466\u20132485 (2015).","journal-title":"Nucleic Acids Res"},{"key":"627_CR180","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-022-01263-x","volume":"15","author":"HL Wu","year":"2022","unstructured":"Wu, H. L. et al. Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy. J. Hematol. Oncol. 15, 45 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"627_CR181","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00262-020-02671-z","volume":"70","author":"JW Rutland","year":"2021","unstructured":"Rutland, J. W. et al. NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. Cancer Immunol. Immunother. 70, 169\u2013176 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"627_CR182","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev-cancerbio-030518-055552","volume":"3","author":"M Dougan","year":"2019","unstructured":"Dougan, M., Dranoff, G. & Dougan, S. K. Cancer immunotherapy: beyond checkpoint blockade. Annu Rev. Cancer Biol. 3, 55\u201375 (2019).","journal-title":"Annu Rev. Cancer Biol."},{"key":"627_CR183","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ebiom.2019.09.003","volume":"48","author":"N Alcala","year":"2019","unstructured":"Alcala, N. et al. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine 48, 191\u2013202 (2019).","journal-title":"EBioMedicine"},{"key":"627_CR184","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas, P. et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 397, 375\u2013386 (2021).","journal-title":"Lancet"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00627-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00627-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T18:10:53Z","timestamp":1732212653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-024-00627-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,15]]},"references-count":184,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1038\/s41698-024-00627-5","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,15]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"133"}}